TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...
Q4 2024 Management View Ana Botín highlighted that 2024 marked the third consecutive year of record results, with profit reaching €12.6B, supported by strong revenue growth and the addition of 8 ...
Increase in Net Income Year over Year Strengthened Balance Sheet to Support Growth Initiatives HONG KONG, Jan. 28, 2025 /PRNewswire/ -- SU Group Holdings ...